Survival after inflammatory bowel disease-associated colorectal cancer in the colon cancer family registry

World Journal of Gastroenterology

Volumn 19, Issue 21, 2013, Pages 3241-3248

  Adams, Scott V ^a   Ahnen, Dennis J ^b   Baron, John A ^c   Campbell, Peter T ^d   Gallinger, Steven ^e   Grady, William M ^a   Lemarchand, Loic ^f   Lindor, Noralane M ^g   Potter, John D ^a   Newcomb, Polly A ^a  

^a USA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^g MAYO CLINIC   (United States)

Author keywords

Cancer survival; Colorectal cancer; Inflammation; Inflammatory bowel disease; Outcomes research

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COLLOID CARCINOMA; COLON DIVERTICULOSIS; COLORECTAL CANCER; DEATH; DISEASE ASSOCIATION; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICROSATELLITE INSTABILITY; OCCULT BLOOD;

EID: 84878525812     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i21.3241     Document Type: Article

References (45)

1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.[PMID:19923578 DOI:10.1056/NEJMra0804647
2. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010; 138:2101.e5-2114.e5.[PMID:20420949
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535.[PMID:11247898
4. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994; 35:1590-1592.[PMID: 7828978
5. O'Connor PM, Lapointe TK, Beck PL, Buret AG. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1411-1420.[PMID:20155848 DOI:10.1002/ibd.21217
6. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287: G7-G17.[PMID:15194558 DOI:10.1152/ajpgi.00079.2004287/1/G7
7. Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene. 2010;29: 3313-3323.[PMID:20400974 DOI:10.1038/onc.2010.109
8. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res. 2011;185: 99-115.[PMID:21822822 DOI:10.1007/978-3-642-03503-6_6
9. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291: 585-590.[PMID:14762037 DOI:10.1001/jama.291.5.585291/5/585
10. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer. 2008;123:1133-1140.[PMID:18528865 DOI:10.1002/ijc.23606
11. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106:1340-1350.[PMID:21407185 DOI:10.1038/ajg.2011.38ajg201138
12. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369:1603-1613.[PMID:17499602 DOI:10.1016/S0140-6736(07)60747-8
13. Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev. 2006;15:1785-1790.[PMID:17035383 DOI:10.1158/1055-9965.EPI-05-0674
14. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294: 914-923.[PMID:16118381 DOI:10.1001/jama.294.8.914
15. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology. 2011; 140: 799-808, Quiz e11.[PMID:21115010 DOI:10.1053/j.gastro.2010.11.041
16. Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD. IL6 genotypes and colon and rectal cancer. Cancer Causes Control. 2007;18:1095-1105.[PMID:17694420 DOI:10.1007/s10552- 007-9049-x
17. Curtin K, Wolff RK, Herrick JS, Abo R, Slattery ML. Exploring multilocus associations of inflammation genes and colorectal cancer risk using hapConstructor. BMC Med Genet. 2010;11:170.[PMID:21129206 DOI:10.1186/1471-2350-11-170
18. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle. 2009; 8: 3267-3273.[PMID:19770594
19. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009; 302: 649-658.[PMID:19671906
20. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, Potter JD, Ulrich CM. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut. 2011; 60: 491-498.[PMID:21051449 DOI:10.1136/gut.2010.221143
21. Sugita A, Greenstein AJ, Ribeiro MB, Sachar DB, Bodian C, Panday AK, Szporn A, Pozner J, Heimann T, Palmer M. Survival with colorectal cancer in ulcerative colitis. A study of102 cases. Ann Surg. 1993;218:189-195.[PMID: 8342999
22. Gyde SN, Prior P, Thompson H, Waterhouse JA, Allan RN. Survival of patients with colorectal cancer complicating ulcerative colitis. Gut. 1984;25:228-231.[PMID: 6698437
23. Ritchie JK, Hawley PR, Lennard-Jones JE. Prognosis of carcinoma in ulcerative colitis. Gut. 1981;22: 752-755.[PMID: 7297924
24. van Heerden JA, Beart RW. Carcinoma of the colon and rectum complicating chronic ulcerative colitis. Dis Colon Rectum. 1980;23:155-159.[PMID: 7379668
25. Jensen AB, Larsen M, Gislum M, Skriver MV, Jepsen P, Nørgaard B, Sørensen HT. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide populationbased Danish study. Am J Gastroenterol. 2006;101:1283-1287.[PMID:16771950
26. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 335-342.[PMID:16527697
27. Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17: 802-808.[PMID:20848547 DOI:10.1002/ibd.21365
28. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, Hall D, Hopper JL, Jass J, Le Marchand L, Limburg P, Lindor N, Potter JD, Templeton AS, Thibodeau S, Seminara D. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2331-2343.[PMID:17982118
29. Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. Cancer. 2011;117: 4948-4957.[PMID:21495019 DOI:10.1002/cncr.26114
30. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248-5257.[PMID: 9823339
31. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, Redston M, Thibodeau SN. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20:1043-1048.[PMID:11844828
32. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offit K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG, Wong WD, Gerald WL, Klimstra DS. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol. 2003;27:1407-1417.[PMID:14576473
33. Poynter JN, Siegmund KD, Weisenberger DJ, Long TI, Thibodeau SN, Lindor N, Young J, Jenkins MA, Hopper JL, Baron JA, Buchanan D, Casey G, Levine AJ, Le Marchand L, Gallinger S, Bapat B, Potter JD, Newcomb PA, Haile RW, Laird PW. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev. 2008;17: 3208-3215.[PMID:18990764
34. Nur U, Shack LG, Rachet B, Carpenter JR, Coleman MP. Modelling relative survival in the presence of incomplete data: a tutorial. Int J Epidemiol. 2010; 39:118-128.[PMID:19858106 DOI:10.1093/ije/dyp309
35. Young JL Jr, Roffer SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual -2000: Codes and Coding Instructions. NIH Publication number 01-4969 ed. Bethesda: National Cancer Institute, 2001
36. Adamo MB, Johnson CH, Ruhl JL, Dickie LA. 2011 SEER Program Coding and Staging Manual. NIH Publication number11-5581 ed. Bethesda: National Cancer Institute, 2011
37. Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time-to-event data. 2nd ed. Hoboken: Wiley-Interscience, 2008
38. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev. 2006; (2): CD000279.[PMID:16625534
39. Aarnio M, Mustonen H, Mecklin JP, Järvinen HJ. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med. 1998; 30: 75-80.[PMID: 9556092
40. Larsen M, Mose H, Gislum M, Skriver MV, Jepsen P, Nørgård B, Sørensen HT. Survival after colorectal cancer in patients with Crohn's disease: A nationwide populationbased Danish follow-up study. Am J Gastroenterol. 2007;102:163-167.[PMID:17037994
41. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.[PMID:15929768 DOI:10.1111/j.1572-0241.2005.41442.x
42. van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005; 54:1573-1578.[PMID:15994215 DOI:10.1136/gut.2005.070896
43. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut. 1994; 35: 651-655.[PMID: 8200559
44. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008;103:1998-2006.[PMID:18796097
45. Loftus CG, Loftus EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn WJ. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007; 13:254-261.[PMID:17206702